Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04734873 · ClinicalTrials.gov registry record · Phase 3
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
A Phase 3 study, sponsored by Corvus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
NCT04734873 is a Phase 3 study that was terminated before completion, run by Corvus Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT04734873, a Phase 3 study, was terminated before completion, sponsored by Corvus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.
Interventions
- DRUG CPI-006 2 mg/kg + SOC
- DRUG CPI-006 1 mg/kg + SOC
- DRUG Placebo + SOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2021-08-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04734873
The ClinicalTrials.gov registry entry for NCT04734873 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corvus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CPI-006 2 mg/kg + SOC is the first listed.
NCT04734873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04734873 about?
NCT04734873 is a clinical study titled "CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients". This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive an...
What is the current status of trial NCT04734873?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2021-02-25. Estimated completion is 2021-08-18.
What interventions are being tested in trial NCT04734873?
The interventions under investigation include: CPI-006 2 mg/kg + SOC (DRUG), CPI-006 1 mg/kg + SOC (DRUG), Placebo + SOC (DRUG).
Who is sponsoring clinical trial NCT04734873?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.